Edition:
United States

Collegium Pharmaceutical Inc (COLL.OQ)

COLL.OQ on NASDAQ Stock Exchange Global Select Market

18.83USD
12:55pm EST
Change (% chg)

$0.25 (+1.35%)
Prev Close
$18.58
Open
$18.76
Day's High
$19.01
Day's Low
$18.70
Volume
59,238
Avg. Vol
142,154
52-wk High
$29.80
52-wk Low
$13.70

Latest Key Developments (Source: Significant Developments)

Collegium Pharmaceutical Q2 Loss Per Share $0.40
Wednesday, 8 Aug 2018 04:01pm EDT 

Collegium Pharmaceutical Inc ::COLLEGIUM REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.40.Q2 REVENUE $73.1 MILLION VERSUS I/B/E/S VIEW $72.2 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.42 -- THOMSON REUTERS I/B/E/S.EXPECTS TO FINISH YEAR WITH AT LEAST $135.0 MILLION IN CASH.  Full Article

Janus Henderson Group Reports 10.1 Pct Passive Stake In Collegium Pharmaceutical
Thursday, 11 Jan 2018 10:44am EST 

Jan 11 (Reuters) - Collegium Pharmaceutical Inc ::JANUS HENDERSON GROUP PLC REPORTS 10.1 PERCENT PASSIVE STAKE IN COLLEGIUM PHARMACEUTICAL AS OF DEC 31, 2017 - SEC FILING.  Full Article

BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical
Thursday, 14 Dec 2017 04:30pm EST 

Dec 14 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL.BIODELIVERY SCIENCES - GOT 90-DAY NOTICE FROM COLLEGIUM REGARDING TERMINATION OF LICENSE AND DEVELOPMENT AGREEMENT FOR ONSOLIS.BIODELIVERY SCIENCES INTERNATIONAL - TERMINATION OF AGREEMENT WILL BE EFFECTIVE ON MARCH 8, 2018.BIODELIVERY SCIENCES - COLLEGIUM TO TERMINATE LICENSE DUE TO ITS AGREEMENT TO COMMERCIALIZE NUCYNTA IMMEDIATE RELEASE, NUCYNTA ER.BIODELIVERY SCIENCES - "WE WILL BE ASSESSING OPTIONS FOR COMMERCIALIZING ONSOLIS".BIODELIVERY SCIENCES - DO NOT CURRENTLY BELIEVE RETURN OF ONSOLIS TO US WILL HAVE MATERIAL IMPACT ON BUSINESS.  Full Article

Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical
Monday, 4 Dec 2017 04:30pm EST 

Dec 4 (Reuters) - Depomed Inc ::DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL.DEPOMED INC - RELOCATION OF COMPANY HEADQUARTERS MID-2018.DEPOMED INC - TRANSACTION IS IMMEDIATELY ACCRETIVE AND IMPROVES 2018 EBITDA OUTLOOK.DEPOMED - PLANS TO RELOCATE ITS CORPORATE HEADQUARTERS FROM NEWARK, SOMETIME IN MID-2018 & IS CURRENTLY EVALUATING POTENTIAL MIDWEST & EAST COAST LOCATIONS.DEPOMED INC - COMPANY WILL REDUCE ITS STAFF BY 40% TO APPROXIMATELY 70 EMPLOYEES AND HEADQUARTERS OFFICE SPACE REQUIREMENT BY 50%.DEPOMED INC - EXPECTS TO SAVE APPROXIMATELY $10 MILLION ANNUALLY AS A RESULT OF HEADQUARTERS RESTRUCTURING AND RELOCATION.DEPOMED INC - WILL ELIMINATE ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING ON NUCYNTA.DEPOMED INC - BY ELIMINATING ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING CO TO REDUCE SG&A EXPENSES BY ABOUT $70 MILLION ON AN ANNUAL BASIS.DEPOMED INC - UNDER TERMS OF AGREEMENT, COLLEGIUM WILL COMMERCIALIZE BOTH NUCYNTA EXTENDED RELEASE AND NUCYNTA IMMEDIATE RELEASE.DEPOMED INC - DEPOMED WILL RECEIVE A ROYALTY RATE ON ALL NUCYNTA REVENUES BASED ON CERTAIN NET SALES THRESHOLDS.  Full Article

Collegium To License Rights To Commercialize Nucynta Franchise
Monday, 4 Dec 2017 04:30pm EST 

Dec 4 (Reuters) - Collegium Pharmaceutical Inc ::COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE.COLLEGIUM PHARMACEUTICAL INC - DEAL IS IMMEDIATELY ACCRETIVE.COLLEGIUM PHARMACEUTICAL INC - ENTERED INTO A DEFINITIVE COMMERCIALIZATION AGREEMENT WITH DEPOMED.COLLEGIUM PHARMACEUTICAL - FOR FIRST FOUR YEARS OF AGREEMENT, COLLEGIUM WILL PAY A MINIMUM ANNUAL LICENSE FEE OF $135.0 MILLION PAID QUARTERLY IN ARREARS.COLLEGIUM PHARMACEUTICAL - FOR FIRST FOUR YEARS OF AGREEMENT, COLLEGIUM WILL ALSO PAY DOUBLE-DIGIT ROYALTIES ON NET SALES ABOVE $233.0 MILLION PER YEAR.COLLEGIUM PHARMACEUTICAL - AFTER 12 MONTHS, CO MAY TERMINATE AGREEMENT WITH TWELVE MONTHS' NOTICE AND PAYMENT OF A $25.0 MILLION TERMINATION FEE.COLLEGIUM PHARMACEUTICAL INC - AFTER FOUR YEARS OF AGREEMENT, COLLEGIUM WILL PAY DOUBLE-DIGIT ROYALTIES ON ALL NET SALES.COLLEGIUM PHARMACEUTICAL INC - TRANSACTION HAS BEEN APPROVED BY COLLEGIUM'S AND DEPOMED'S BOARD OF DIRECTORS.COLLEGIUM PHARMACEUTICAL INC - EXPECTS TO SUPPORT NUCYNTA FRANCHISE WITH ITS EXISTING RETAIL AND HOSPITAL FIELD FORCES.COLLEGIUM PHARMACEUTICAL INC - WILL RECEIVE AN EXCLUSIVE SUBLICENSE TO COMMERCIALIZE NUCYNTA AND NUCYNTA ER IN UNITED STATES.  Full Article

Collegium reports third quarter loss of $0.45 per share
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Collegium Pharmaceutical Inc :Collegium reports third quarter financial results and provides corporate update.Q3 loss per share $0.45.Q3 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Collegium receives FDA approval for sNDA for Xtampza® ER
Tuesday, 7 Nov 2017 08:30am EST 

Nov 7 (Reuters) - Collegium Pharmaceutical Inc :Collegium receives FDA approval for sNDA for Xtampza® ER.  Full Article

Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza ER
Monday, 6 Nov 2017 08:45am EST 

Nov 6 (Reuters) - Collegium Pharmaceutical Inc :Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza® ER.Collegium Pharmaceutical - ‍FDA hasn't requested any additional scientific information or data regarding co's snda for Xtampza ER​.  Full Article

Sectoral Asset Management reports 7.4 percent passive stake in Collegium Pharmaceutical as of December 31, 2016
Friday, 10 Feb 2017 10:14am EST 

Sectoral Asset Management Inc :Sectoral Asset Management reports a 7.4 percent passive stake in Collegium Pharmaceutical as of December 31, 2016 - SEC filing.  Full Article